Amyris, Inc., a leading synthetic biotechnology company based in Emeryville (California), launched “Baby Cream to Powder” under its Pipette™ baby brand giving caring parents more choice and keeping babies safe. This safe, talc-free alternative to baby powder goes on as an easy-to-apply cream to prevent and treat diaper rash and irritation and transforms into a silky powder on skin, eliminating the risk of powder inhalation. The announcement by Amyris comes on the heels of news that the largest and leading provider of baby care products will stop selling talcum-based baby powder in the U.S. and Canada amidst questions about its product safety.
Amyris, Inc., a leader in the development and production of sustainable ingredients for the Health & Wellness, Clean Beauty and Flavors & Fragrances markets, successfully shipped the first cannabinoid to its partner, LAVVAN. Amyris is also well on its way to the shipment of a second cannabinoid in the first half of 2020.
Amyris Inc., the US company which develops and produces sustainable ingredients for the Flavors & Fragrances, Health & Wellness and Clean Beauty markets, launched Pipette, a new brand reinventing clean personal care for babies and moms using the fewest possible ingredients from the purest sources.
Amyris, a leader in the development and production of sustainable ingredients for the Health & Wellness, Clean Beauty and Flavors & Fragrances markets, sold its Vitamin E royalty agreement to Koninklijke DSM N.V. (Royal DSM). This agreement assigns Amyris’s rights to Vitamin E royalties to DSM in exchange for total consideration of approximately $57 million. In addition, DSM and Amyris have agreed to a further manufacturing cooperation for Amyris products at DSM’s Brotas facility that provides additional capacity and lower cost of goods sold with an expected approximate aggregate benefit of $30–$40 million over the next three years. The expected economic benefit of both agreements to Amyris is approximately $90 million.
Amyris, Inc., a California-based leader in the development and production of sustainable ingredients for the Health & Wellness, Clean Beauty and Flavors & Fragrances markets, signed a binding term sheet for a planned cannabinoid development, licensing and commercialization partnership valued at up to $255 million (not including significant royalties once the products are commercialized) with a confidential partner. The $255 million in payments include an upfront payment and the remainder are linked to milestones that are expected over the next 12-36 months following the signing of a definitive final agreement.
Amyris, Inc., the U.S. industrial bioscience company, and Chevron Products Company, a division of Chevron U.S.A. Inc., announced that Novvi LLC and Chevron have entered into an agreement to jointly develop and bring to market novel renewable base oil technologies. Terms of the transaction were not disclosed.
Amyris, Inc., the industrial bioscience company headquartered in Emeryville, California, has successfully collaborated with its fragrance partner, Firmenich, the world’s largest privately-owned fragrance and flavor company, to support the development and commercialization of Z11.
Amyris, the U.S. industrial bioscience company led by John Melo, closed the second and final tranche of its previously announced financing. The second tranche of $50 million in a private placement was led by a $25 million investment from Koninklijke DSM N.V. (Royal DSM) with the remaining $25 million contributed by Vivo Capital.
Amyris, the U.S. industrial bioscience company, and the Government of Queensland, Australia, announced the next step their plans to develop a leading industrial biotechnology hub in Southeast Asia. Plans call for developing a new production plant with support from local partners to produce Amyris’s sugar cane-based ingredient called farnesene, which is used in products including cosmetic emollients, fragrances, nutraceuticals, polymers, and lubricants.
Amyris, Inc., the U.S. industrial bioscience company, and Koninklijke DSM N.V. (Royal DSM), the Dutch global science-based company active in health, nutrition and materials, have agreed for DSM to make an equity investment in Amyris. At the same time, the companies will enter into a development cooperation focused on products for the global health and nutrition markets (including vitamins and other nutritional ingredients).